

AD _____

Award Number: DAMD17-96-1-6134

TITLE: Role of Bone Sialoproteins in Osseous Metastasis of Breast Cancer

PRINCIPAL INVESTIGATOR: Michele Dougherty
Matthew Ellis, Ph.D.

CONTRACTING ORGANIZATION: Georgetown University
Washington DC 20057

REPORT DATE: October 1999

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release
Distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 4

20001027 009

-REPORT DOCUMENTATION PAGE-Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE October 1999	3. REPORT TYPE AND DATES COVERED Final (1 Jul 96 - 30 Sep 99)	
4. TITLE AND SUBTITLE Role of Bone Sialoproteins in Osseous Metastasis of Breast Cancer			5. FUNDING NUMBERS DAMD17- 96-1-6134	
6. AUTHOR(S) Michele Dougherty Matthew Ellis, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Georgetown University Washington, DC 20057 e-mail: doughem2@gunet.georgetown.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distributed unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words) Recently, antibodies to the growth factor receptor ErbB2 have been established as a valid therapeutic approach in the treatment of breast cancer. Because breast cancers can express a number of growth factor receptors the evaluation of antibodies targeting other growth factor receptors implicated in the progression of breast cancer is extremely important. We have explored the potential of blocking antibodies targeting the insulin-like growth factor 1 receptor (IGF1R) to inhibit the growth of breast cancer cells using an <i>in vitro</i> model. Limited dilution cloning of T47D:A18 cells in estrogen free media generated the panel of T47D:C4:nW clones. These cell lines were originally estrogen receptor negative. We assessed the status of ER and IGF1R in these cells lines and found them to be a useful model to determine the effects of IGF1R blocking antibodies.				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 14	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-99)
Prescribed by ANSI Std. Z39-18
298-102

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

_____ Where copyrighted material is quoted, permission has been obtained to use such material.

_____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

_____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

☒ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

_____ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

_____ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

_____ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

_____ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Michele K Dougherty 10/29/99

_____ PI - Signature

Date

Table of Contents

Front Cover	1
Report Documentation Page	2
Foreword	3
Introduction	5
Current Progress	7
Conclusions and Future Directions	9
Bibliography	11
Appendix I – Key Research Accomplishments	13
Appendix II – Reportable Outcomes	14

The work proposed for the funding year involved determining the effects of insulin like growth factor 1 receptor (IGF1R) inhibitory antibodies 24-57 and 24-60 (1), in estrogen receptor (ER) positive, IGF1R positive MCF-7 cells. Shortly after beginning work on this project, our lab obtained a set of ER negative T47D clonal cell lines, designated T47D:C4:nW, and the parental ER positive T47D:A18 cell line (2). Since IGF1R expression can be regulated by estrogen receptor, we anticipated that T47D:C4:nW cells would no longer express IGF1R. This type of *in vitro* model would provide us with a valuable negative control for determining the effects of these antibodies on IGF1 mediated signaling. The goals for this project subsequently included determining 1) the status of the insulin like growth factor system in T47D:C4:nW cells, 2) the effects of IGF1 treatment in these cells, 3) the effect of antibody treatment on growth and survival of these cell lines in the presence of IGF1 and other growth factors.

Background


Insulin like growth factor 1 receptor (IGF1R) is a tetrameric transmembrane tyrosine kinase receptor. Ligands for IGF1R include IGF1, IGF2 and insulin (3). Ligand stimulation of the receptor facilitates interaction with a number of downstream effector molecules including Shc, Crk and the family of insulin receptor substrate (IRS) proteins (4, 5, 6, 7). Interaction of activated IGF1R with multiple downstream effectors suggests several cellular effects. Consistent with these observations, IGF1R has been shown to influence mitogenesis, apoptosis and cell motility (8, 9, 10, 11). The phenotype of IGF1R knockout mice suggests that the receptor plays a role in normal growth and development (12). Additionally, IGFs synergize with estrogen to facilitate normal mammary gland formation in a mouse model (13).

IGF1R activity is required *in vitro* for growth and maintaining the transformed phenotype. IGF1R-deficient fibroblasts exhibit a reduced growth rate and are resistant to transformation (14). IGF1 can positively regulate growth of MCF-7 breast cancer cells, and synergize with estrogen to generate a more potent mitogenic signal in these cells (15). Anti-apoptotic effects of IGF1 treatment have been observed in breast cancer cells treated with chemotherapeutic agents (16, 17). Numerous animal models have demonstrated the necessity of IGF1R activity for tumorigenesis (18, 19, 20, 21, 22). Therapeutic strategies targeting IGF1R, including antisense and antibody therapies (18, 19, 22), have shown efficacy in some of these models. These observations support the conclusion that IGF1R contributes to the growth and survival of cancer cells *in vitro* and *in vivo*.


IGF1R is expressed in numerous human cancers including breast, liver, skin and kidney. In breast cancer, IGF1R overexpression has been observed in 80% of cases (13, 23). IGF1R expression often associates with ER and progesterone receptor status and is therefore considered a favorable prognostic marker (23, 24, 25). However, IGF1R expression has also been observed in ER negative breast cancer and is associated with a decrease in overall survival (26, 27)]. The ability of IGF1R to mediate cell survival (anti-apoptotic) signals has generated the hypothesis that IGF1R may render ER negative IGF1R positive breast cancer cells less sensitive to the effects of cytotoxic chemotherapy (27, 28)]. These observations indicate IGF1R may contribute to growth and survival of both ER positive and ER negative breast cancer. Therapeutic intervention targeting IGF1R may prove beneficial for slowing tumor growth and increasing the efficacy of adjuvant chemotherapy.

Current Progress


T47D:C4:nW cells were generated in the laboratory of Dr. VC Jordan by limited dilution cloning of ER positive T47D cells in estrogen free conditions. The panel of clones was initially negative for expression of the estrogen receptor. During culture in media supplemented with 10% fetal bovine serum, some of the cell lines have



re-expressed ER (Fig 1). Using RNase protection assays we have observed T47D:C4:9W and T47D:C4:2W (lane 5&6) cells maintain an ER negative phenotype during culture in 10% FBS. T47D:C4:12W and T47D:C4:8W (lane 3&4) cells exhibit intermediate levels of ER while T47D:C4:10W (lane 2) cells express ER at levels comparable to the parental T47D:A18 cells (lane 1). Consistent with these observations, all of the C4:nW clones have downregulated expression of IGF1R to levels undetectable by western blot, with the



exception of T47D:C4:12W cells (Fig 2, lane 8). Insulin receptor (IR) and insulin like growth factor 2 receptor (IGF2R) expression are similar among the parental cell line and C4:*n*W clones(data not shown). IRS-1 expression is downregulated in T47D:C4:*n*W clones (Fig 3) IRS-1 is a target for activated IGF1R, we have analyzed the activity of IGF1R following stimulation with IGF1 by monitoring tyrosine phosphorylation of IRS-1. Not surprisingly, IRS-1 phosphorylation is substantially decreased in ER negative T47D:C4:*n*W clones as compared to the parental T47D:A18 cells (Fig 3 compare lanes 3-7 with lane 2). These results suggest that IGF1R participates in growth regulation of




T47D:A18 cells, while C4:*n*W clones are no longer dependent on IGF1R for growth or survival.

We have attempted to confirm that C4:*n*W cells no longer respond to the mitogenic effects of IGF1 or IGF2 using 96-well plate growth assays. These assays have been conducted in both serum free and low serum (0.1% FBS) conditions. However, we have not seen any differences in proliferation of T47D:A18 cells in the absence or presence of IGF in these conditions. Consequently, we are utilizing alternate methods to

confirm or refute these results. Currently, growth assays are being conducted in 24 well plates. Proliferation is assessed by counting cells in the presence of trypan blue to distinguish live cells and expressed as an increase in absolute cell number over time.

The 24-60 IGF1R inhibitory antibody was initially available as a crude ascites fluid. We utilized this preparation in experiments to evaluate the effect 24-60 on IRS-1 phosphorylation following IGF treatment (Fig. 4). These experiments were conducted in NWT21 cells, NIH 3T3 cells engineered to overexpress IGF1R. The results indicate



24-60 antibody can inhibit activation of the receptor in the presence of IGF1, suggesting this antibody can be an effective inhibitor of signaling through IGF1R. Significantly, no IRS-1 phosphorylation was observed in the absence of IGF1 stimulation suggesting that the antibody cannot activate the receptor. A collaboration with Novartis Pharmaceuticals will provide purified 24-60 antibody in milligram quantities allowing us to confirm and extend these results.

Conclusions and Future Directions

The data presented here describe an *in vitro* model that will be utilized to determine the effects of purified IGF1R inhibitory antibodies on growth and survival of

breast cancer cells. This model will allow us to determine the specificity of the antibodies for inhibiting IGF1R signaling pathways since it includes IGF1R positive and IGF1R negative cell lines from a similar genetic background. Preliminary results indicate the 24-60 antibody can efficiently block activation of IGF1R and should be further studied for its potential clinical application.

BIBLIOGRAPHY

1. Soos, M., Field, C., Lammers, R., Ullrich, R., et al. A panel of monoclonal antibodies for the type I Insulin-like growth factor receptor. *J. Biol. Chem* 267:12955-12963, 1992.
2. Pink, J.J., Bilimoria, M.M., Assikis, J., Jordan, V.C. Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation. *Br. J. Cancer* 74:1227-1236, 1996.
3. Sepp-Lorenzino, L. Structure and function of the insulin-like growth factor I receptor. *Breast Cancer Res Treat* 47:235-53, 1998.
4. Dey, B.R., Frick, K., Lopaczynski, W., Nissley, S.P., et al. Evidence for the direct interaction of the insulin-like growth factor 1 receptor with IRS-1, Shc and Grb10. *Mol. Endo.* 10:631-641, 1996.
5. Beitner-Johnson, D., Blakesley, V.A., Shen-Orr, Z., Jimenez, M., et al. The proto-oncogene c-Crk associates with insulin receptor substrate-1 and 4PS. *J. Biol. Chem.* 271:9287-9290, 1996.
6. Myers, M.G., Jr., Sun, X.J., White, M.F. The IRS-1 signaling system. *Trends Biochem Sci* 19:289-93, 1994.
7. Skolnik, E.Y., C-H., L., Batzer, A., Vicentini, L.M., et al. The SH2/SH3 domain containing protein GFR2 interacts with tyrosine phosphorylated IRS-1 and Shc: implications for control of ras signaling. *EMBO J.* 12:1929-1936, 1993.
8. Dunn, S.E., Ehrlich, M., Sharp, N.J., Reiss, K., et al. A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. *Cancer Res* 58:3353-61, 1998.
9. Coppola, D., Ferber, A., Miura, M., Sell, C., et al. A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. *Mol. Cell. Bio.* 14:4588-4595, 1994.
10. Guvakova, M., Surmacz, E. Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells. *Exp Cell Res* 231:149-62, 1997.
11. O'Connor, R., Kauffmann-Zeh, A., Liu, Y., Lehar, S., et al. Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis. *Molecular and Cellular Biology* 17:427-435, 1997.
12. Lui, J., Baker, J., Perkins, A., Robertson, E., et al. Mice carrying null mutations of the the genes encoding insulin-like growth factor I (*igf-I*) and type I IGF receptor (*igf-Ir*). *Cell* 75:59-72, 1993.
13. Kleinberg, D. Role of IGF-I in normal mammary development. *Breast Cancer Res Treat* 47:201-208, 1998.
14. Baserga, R. The insulin-like growth factor I receptor: a key to tumor growth? *Cancer Res.* 55:249-252, 1995.
15. Thorsen, T., Lahooti, H., Rasmussen, M., Aakvaag, A. Oestradiol treatment increases the sensitivity of MCF-7 cells for the growth stimulatory effect of IGF-I. *J Steroid Biochem Mol Biol* 41:537-40, 1992.
16. Dunn, S.E., Hardman, R.A., Kari, F.W., Barrett, J.C. Insulin-like growth factor 1 alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. *Cancer Research* 57:2687-2693, 1997.
17. Gooch, J.L., Van Den Berg, C.L., Yee, D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death--proliferative and anti-apoptotic effects [In Process Citation]. *Breast Cancer Res Treat* 56:1-10, 1999.
18. Resnicoff, M., Sell, C., Rubini, M., Coppola, D., et al. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. *Cancer Res.* 54:2218-2222, 1994.
19. Resnicoff, M., Coppola, D., Sell, C., R., R., et al. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. *Cancer Res.* 54:4848-4850, 1994.
20. Liu, X., Turbyville, T., Fritz, A., Whitesell, L. Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice. *Cancer Res* 58:5432-8, 1998.

21. Brunner, N., Yee, D., Kern, F., Spang-Thomsen, M., et al. Effect of endocrine therapy on growth of T61 human breast cancer xenographs is directly correlated to a specific down-regulation of insulin-like growth factor II (IGF-II). *Eur J Cancer* 29A:562-569, 1993.
22. Arteaga, C.L., Osborne, C.K. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. *Cancer Res* 49:6237-41, 1989.
23. Papa, V., Gliozzo, B., Clark, G.M., McGuire, W.L., et al. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. *Cancer Res* 53:3736-40, 1993.
24. Bonnetterre, J., Peyrat, J., Beuscart, R., Demaille, A. Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. *Cancer Res* 50:6931-5, 1990.
25. Foekens, J.A., Portengen, H., van Putten, W.L.J., Trapman, A.M.A.C., et al. Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. *Cancer Res* 49:7002-9, 1989.
26. Railo, M., von Smitten, K., Pekonen, F. The prognostic value of insulin-like growth factor-I receptor in breast cancer patients. Results of a follow-up study on 126 patients. *Eur J Cancer* 30A:307-11, 1994.
27. Ellis, M.J., Jenkins, S., Hanfelt, J., Redington, M.E., et al. Insulin-like growth factors in human breast cancer. *Breast Cancer Res Treat* 52:175-84, 1998.
28. Railo, M.J., Smitten, K.V., Pekonen, F. The prognostic value of insulin like growth factor 1 in breast cancer patients. Results of a follow-up study on 126 patients. *European J. of Cancer* 30A:307-311, 1994.

Appendix I

Research Accomplishments

1) Demonstrated status of insulin like growth factor 1 receptor (IGF1R) expression and activation in parental T47D:A18 breast cancer cells and C4:nW ER negative, IGF1R negative clones.

2) Demonstrated IGF1R inhibitory potential of the 24-60 antibody in IGF1R over-expressing NWT21 cells.

Appendix II

Reportable Outcomes

1) Abstract and Poster presentation at 1999 AACR Meeting, Philadelphia, PA

Dougherty, M.K., Schumaker, L.M., Jordan, V.C., Ellis, M.J. Status of the insulin-like growth factor network in an estrogen receptor negative T47D breast cancer cell clone. Proceedings AACR 40, Abstract #4042, 1999.